Navigation Links
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
Date:5/4/2011

y Street, Suite 3700, San Francisco, California 94104, or by phone at (415) 364-2720.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
2. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
5. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
8. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
9. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Smile Train and its technology partner BioDigital have been ... among leading global health innovations in The Hive at ... Washington, D.C. at The John F. Kennedy ... Train is honored to be represented through our partnership ... health and medicine that TEDMED unites each year," said ...
(Date:7/25/2014)... -- CVS Caremark Corporation (NYSE: CVS ) will ... 2014, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will ... the CVS Caremark website for all interested parties.  To ... will be archived and available on the web site ...
(Date:7/25/2014)... Cardinal Health will today name three of the nation,s ... Independent Pharmacy Best Practices Competition, during the company,s ... gatherings of independent pharmacists. The Best ... Ohio , Tennessee and ... implementing exceptionally creative methods that demonstrate how independent pharmacies ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6
... 1, 2012  Ultragenyx Pharmaceutical Inc., a biotechnology company ... genetic disorders, today announced results from a first-in-human, ... with hereditary inclusion body myopathy (HIBM) showing that ... profile on absorption after oral administration.  UX001 is ...
... (OTC Bulletin Board: NWBO ) (NW Bio) today announced ... received approval of a major grant from the Sachsische Aufbau ... will reimburse fifty percent (50%) of the costs for manufacturing ... for brain cancer at up to ...
Cached Medicine Technology:Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 3Northwest Bio Awarded $5.5 Million German Government Grant 2Northwest Bio Awarded $5.5 Million German Government Grant 3Northwest Bio Awarded $5.5 Million German Government Grant 4
(Date:7/26/2014)... York (PRWEB) July 26, 2014 The ... in state and federal litigations since the 2012 recall ... surpassed 3,700 filings, Bernstein Liebhard LLP reports. According to ... least 2,064 cases have been filed in the New ... Hip Stem and the ABG II Modular Hip Stem ...
(Date:7/26/2014)... 2014 As reported by Lauren ... based on 3 factors: smaller spaces, multi-generational access, and ... trend of 2014 lists, including this article on ... Amerec , a leading manufacturer of steam bath generators, ... due to smaller spaces and an effort to reduce ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... Dallas, TX (PRWEB) July 26, 2014 ... sclerosis or encephalomyelitis disseminata, is an inflammatory disease ... in the brain and spinal cord are damaged. ... the nervous system to communicate, resulting in a ... mental, and sometimes psychiatric problems. Multiple sclerosis takes ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 Another DePuy Pinnacle ... Orthopedics, Inc., has been filed by Wright & Schulte LLC. ... on behalf of an Erie County, Ohio man who ... left hip and groin since receiving his Pinnacle Hip implant ... man will be forced to undergo a complex and risky ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5
... THURSDAY, Nov. 18 (HealthDay News) -- New research supports the ... may not have an increased risk for cancer, as some ... drugs for people with high blood cholesterol levels, which are ... Zocor. "Three or four years ago there was a ...
... survey from The Commonwealth Fund finds that adults in the ... other industrialized nations to go without health care because of ... even when insured, and have disputes with their insurers or ... report, the findings highlight the need for Affordable Care Act ...
... vitamin D receptors on cancer cells has prompted encouraging ... in men with prostate cancer that has become resistant ... II(a) clinical trial will be presented at the 22nd ... in Berlin today (Thursday). The trial found that when ...
... cancer cells to repair damage to their DNA has shown ... patients with a range of solid tumours, many of whom ... have seen their tumours shrink or stabilise for periods of ... will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on ...
... November 2, 2010) Uniting Against Lung Cancer (Uniting) announces ... Research." This year,s recipient is Avrum Spira, M.D., ... and Director, Translational Bioinformatics Program, Clinical and Translational Science ... is intended for the research lab and its leader ...
... of the Care New England health care system, recently unveiled ... immediate action if they have concerns about the care being ... called the Family Activated Safety Team (FAST) at Kent and ... will serve as a resource for patients and family members ...
Cached Medicine News:Health News:Long-Term Statin Use Won't Up Cancer Risk: Study 2Health News:US adults most likely to forgo care due to cost, have trouble paying medical bills 2Health News:US adults most likely to forgo care due to cost, have trouble paying medical bills 3Health News:US adults most likely to forgo care due to cost, have trouble paying medical bills 4Health News:US adults most likely to forgo care due to cost, have trouble paying medical bills 5Health News:New drug targets vitamin D receptors in hormone resistant prostate cancers 2Health News:New drug targets vitamin D receptors in hormone resistant prostate cancers 3Health News:PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans 2Health News:PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans 3Health News:Boston University researcher lauded for leading-edge lung cancer research efforts 2Health News:Hospitals introduce family-activated rapid response programs 2
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... C.B.S.SCIENTIFIC offers four different Series II ... the EPS-4000-II, and the EPS-6000-II. These ... constant current, and constant power operating ... powerful 300 milliamps maximum current/300 watts ...
... The PowerPac Basic power supply, ... output of 10-300 V, 4-400 ... unit contains a built-in switch ... with the appropriate power cord. ...
Medicine Products: